Xeris Pharmaceuticals | XERS - Selling And Administration Expenses


Xeris Pharmaceuticals reported $53.14M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Celltrion KRW 9.32B 3.39B Mar/2026
Cspc Pharmaceutical CNY 1.87B 95.62M Dec/2025
Deva Holding AS TRY 462.26M 48.18M Sep/2023
Dianthus Therapeutics USD 12.47M 5.89M Mar/2026
Divis Laboratories Ltd INR 3.4B 10M Jun/2025
Eli Lilly USD 2.93B 198M Mar/2026
Kangmei Pharma CNY 237.06M 37.35M Mar/2026
Knight Therapeutics CAD 35.45M 4.43M Dec/2025
Laboratorios Farma EUR 35.32M 2.75M Jun/2025
Malin Corporation EUR 1.1M 400K Dec/2024
Medical Developments International AUD 2.84M 4.19M Dec/2025
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Neuren Pharmaceuticals AUD 3.74M 2.5M Dec/2025
Organigram Holdings CAD 22.01M 14.28M Mar/2026
Ovoca Bio EUR 632K 2.33M Jun/2025
Pacira USD 83.88M 7.99M Mar/2026
Perrigo USD 267.3M 11.4M Mar/2026
Pharma Mar EUR 15.31M 2M Mar/2026
Qiagen NV USD 153.88M 10.77M Dec/2025
Sartorius EUR 221.3M 500K Mar/2026
Sino Biopharmaceutical CNY 7.54B 2.23B Jun/2025
Supernus Pharmaceuticals USD 118.23M 4.16M Mar/2026
Tilray USD 24.85M 1.7M Sep/2025
Zealand Pharma A/S 91.81M 99.04M Dec/2025
Zz Pientze Pharmaceu CNY 214.31M 42.4M Mar/2026